Product Pipeline

Candidate & Indication Development Stage
R & D Preclinical Phase 1 Phase 2 Phase 3
Iomab-B (CD45) (apamistamab-I-131) (Fully Enrolled)
BMT conditioning1
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Iomab-ACT (CD45) (apamistamab-I-131) GeneTx and Cell therapy conditioning
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A (CD33) and CLAG-M Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A (CD33) and Venetoclax Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A (CD33) and Venetoclax with HMA Planned
Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
AWE Technology Platform Astellas Collaboration, Actinium-225 conjugated select Astellas targeting agents, Theranostics for solid tumors
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
AWE Technology Platform AVEO Collaboration, Actinium-225 HER3 targeted radiotherapy for solid tumors.
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
AWE Technology Platform EpicentRX Collaboration, Actimab CD47-SIRPĪ± immunotherapy combination, acute myeloid leukemia
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
AWE Technology Platform Actinium-225 conjugated to daratumumab
CD38 targeting agent for multiple myeloma
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  1. BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.